- Home
- MNMD
as 06-20-2025 3:38pm EST
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
| Founded: | 2019 | Country: | United States |
| Employees: | 74 | City: | NEW YORK |
| Market Cap: | 541.7M | IPO Year: | N/A |
| Target Price: | $26.29 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.70 - $10.44 | Next Earning Date: | 08-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Mind Medicine (MindMed) Inc. (MNMD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sullivan Mark | MNMD | Chief Legal Officer | Mar 25 '25 | Sell | $6.74 | 6,576 | $44,322.24 | 316,621 | |
| Barrow Robert | MNMD | Chief Executive Officer | Mar 25 '25 | Sell | $6.74 | 21,208 | $142,941.92 | 856,556 | |
| Karlin Dan | MNMD | Chief Medical Officer | Mar 25 '25 | Sell | $6.74 | 6,836 | $46,074.64 | 446,177 | |
| Liao Carrie | MNMD | Chief Accounting Officer | Mar 25 '25 | Sell | $6.74 | 2,347 | $15,818.78 | 144,923 |
Latest Mind Medicine (MindMed) Inc. News
MNMD Breaking Stock News: Dive into MNMD Ticker-Specific Updates for Smart Investing
TipRanks
2 days ago
Trump Trade: President said to weigh possible U.S. strike against Iran
TipRanks
2 days ago
Psychedelic advocates hopeful Trump administration will support space, STAT says
WSJ
2 days ago
This Illegal Psychedelic Is Hailed as a ‘Revolutionary Breakthrough’
Business Wire
12 days ago
MindMed Announces New Employee Inducement Grants
Business Wire
24 days ago
MindMed to Participate in June Investor Conferences
Business Wire
25 days ago
MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer
Business Wire
a month ago
MindMed Announces New Employee Inducement Grants
Business Wire
a month ago
MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference
Compare MNMD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MNMD Mind Medicine (MindMed) Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.